Compare Amphastar Pharmaceuticals Inc (AMPH) vs Oatly Group AB - ADR (OTLY) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

OTLY trades at $9.85, up 2.82% today, with a bullish technical signal from ADX indicators. Revenue growth is steady, reaching $862M in 2025, but profitability remains elusive with a net income margin of -17.06%. The company continues to burn cash, though the rate has improved from previous years. Recent news includes new product launches in Canada and an upcoming Q2 2026 earnings report on July 22, 2026.

The outlook is mixed: strong brand presence and revenue growth offer potential, but persistent losses, high debt, and negative cash flow pose significant risks. Analyst sentiment is divided, with 44% recommending buy and 50% hold. Investment hinges on OTLY's ability to achieve profitability and manage its cash runway effectively.